SCHEMBL6834975

SCHEMBL6834975

COc1ccc(Oc2ccc(N(C(N)=O)c3cc4ccccc4cc3OC)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
KEAP1 Q14145 5/20 0.40
NFE2L2 Q16236 5/20 0.40
RNF4 P78317 1/20 0.40
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
POLB P06746 1/20 0.39
LTA4H P09960 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
MAPT P10636 1/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PGR P06401 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13388590 0.87 KMT2A (0.47) MEN1NPC1KMT2AALDH1A1KDM4E
SCHEMBL27517610 0.83 NPC1 (0.46) PARP10MEN1NPC1KMT2AALDH1A1
SCHEMBL13388550 0.79 PARP10 (0.40) PARP10NPC1ALDH1A1KDM4EMAPT
SCHEMBL13388527 0.79 ALDH1A1 (0.39) PARP10MEN1NPC1KMT2AALDH1A1
SCHEMBL13388901 0.79 ALDH1A1 (0.38) NPC1KMT2AALDH1A1KDM4EHPGD
SCHEMBL4585313 0.79 LMNA (0.54) MEN1KMT2AALDH1A1KDM4EPOLB
SCHEMBL5608496 0.79 KDM4E (0.40) MEN1NPC1KMT2AALDH1A1KDM4E
SCHEMBL13388585 0.77 NPSR1 (0.40) PARP10MEN1KMT2AKEAP1NFE2L2
SCHEMBL13388556 0.76 PARP15 (0.44) PARP10MEN1KMT2AALDH1A1KDM4E
SCHEMBL28844152 0.76 TRPM8 (0.56) PARP10MEN1NPC1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US claimed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 PARP10 2407/4885MEN1 4566/4885NPC1 2972/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 PARP10 3799/4885MEN1 4158/4885NPC1 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.